Serum interferon‐gamma‐inducible protein‐10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. Issue 12 (17th February 2014)

• Record Type: Journal Article
• Authors: Matsuura, Kentaro; Watanabe, Tsunamasa; Iijima, Sayuki; Murakami, Shuko; Fujiwara, Kei; Orito, Etsuro; Iio, Etsuko; Endo, Mio; Kusakabe, Atsunori; Shinkai, Noboru; Miyaki, Tomokatsu; Nojiri, Shunsuke; Joh, Takashi; Tanaka, Yasuhito
• Is Part Of: Hepatology research. Volume 44:Issue 12(2014:Dec.)
• Page Start: 1208
• Page End: 1216
• Publication Date: 2014-02-17
• Subjects: hepatitis C -- IL28B -- interferon -- interferon‐γ‐inducible protein‐10 -- ribavirin -- telaprevir; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12294
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: Several studies have shown that high pretreatment concentrations of serum interferon‐γ‐inducible protein‐10 (IP‐10) are correlated with non‐response to pegylated interferon (PEG‐IFN) plus ribavirin (RBV) for chronic hepatitis C (CHC). However, there are few reports on their effect on the Asian population. Methods: We enrolled 104 Japanese genotype 1 CHC individuals treated with PEG‐IFN/RBV and 45 with PEG‐IFN/RBV/telaprevir, and evaluated the impact of pretreatment serum IP‐10 concentrations on their virological responses. Results: The pretreatment serum IP‐10 concentrations were not correlated with IL28B genotype. The receiver–operator curve analysis determined the cut‐off value of IP‐10 for predicting a sustained virological response (SVR) as 300 pg/mL. In multivariate analysis, the IL28B favorable genotype and IP‐10 concentration of less than 300 pg/mL were independent factors for predicting SVR. In a subgroup of patients with the IL28B favorable genotype, the SVR rate was higher in the patients with IP‐10 of less than 300 than in those with 300 pg/mL or more, whereas no patient with the IL28B unfavorable genotype and IP‐10 of 300 pg/mL or more achieved SVR. Among the patients treated with PEG‐IFN/RBV/telaprevir, low pretreatment concentrations of serum IP‐10 were associated with a very rapid virological response, defined as undetectable HCV RNA at week 2 after the start of therapy. Conclusion: Pretreatment serum IP‐10 concentrations are associated with treatment efficacy in PEG‐IFN/RBV and with early viral kinetics of hepatitis C virus in PEG‐IFN/RBV/telaprevir therapy.